人乳头瘤病毒相关口咽鳞状细胞癌去强化放化疗对吞咽功能的保留作用
回顾性比较78例人乳头瘤病毒相关口咽鳞状细胞癌患者,40例接受去强化放化疗(6周、60 Gy),38例接受标准放化疗(7周、70 Gy),于治疗前及治疗后6至8周行改良钡餐吞咽检查。去强化组总体吞咽功能障碍风险有降低提示(OR 0.62,P=0.07),喉部渗透(OR 0.63,P=0.12)和咽部残留(OR 0.61,P=0.08)风险亦呈降低提示。作者结论认为6周60 Gy去强化放化疗较7周70 Gy似能更好地保留基线吞咽功能。
要点
- 去强化组总体吞咽功能障碍风险有降低提示(OR 0.62,P=0.07),未达统计学显著。
- 去强化组喉部渗透(OR 0.63,P=0.12)和咽部残留(OR 0.61,P=0.08)风险亦呈降低提示。
- 去强化组患者报告吞咽功能变化轻微。
核心结论
- 与7周70 Gy相比,6周60 Gy去强化放化疗似乎能更好地保留基线吞咽功能(依据客观改良钡餐吞咽评估)。
- 接受去强化放化疗的患者报告吞咽功能变化轻微。
研究设计与样本
- 回顾性研究,纳入78例人乳头瘤病毒相关口咽鳞状细胞癌患者,均于治疗前及治疗后6至8周行改良钡餐吞咽检查。
- 40例接受去强化放化疗(60 Gy图像引导放疗联合每周顺铂30 mg/m2),38例接受标准放化疗(70 Gy图像引导放疗联合由肿瘤内科医生选择的化疗方案)。
- 采用单因素和多因素分析比较两组喉部渗透、误吸和咽部残留差异,并用多因素逻辑回归确定治疗对吞咽功能的总体效应。
主要发现
- 去强化放化疗组总体吞咽功能障碍风险有降低提示(OR 0.62,P=0.07),喉部渗透风险有降低提示(OR 0.63,P=0.12),咽部残留风险有降低提示(OR 0.61,P=0.08)。
- 去强化组欧洲癌症研究与治疗组织头颈癌生活质量模块吞咽相关评分(1-4分,分数越高越差)治疗前与2年后均值:液体为1.4和1.2,泥状食物为1.2和1.1,固体食物为1.5和1.7,吞咽时呛咳为1.0和1.3,复合评分为9.0和10.8。
- 去强化组患者报告版常见不良事件评价标准吞咽困难评分(1-5分,分数越高越差)治疗前与2年后均值分别为1.5和1.8。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the swallowing function in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma treated with de-intensified chemoradiation therapy (6 weeks, 60 Gy) versus those receiving standard-of-care chemoradiation therapy (7 weeks, 70 Gy). METHODS AND MATERIALS: A retrospective review was conducted of 78 patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma with modified barium swallow studies pretreatment and 6 to 8 weeks posttreatment. The swallowing function was objectively scored for penetration, aspiration, and pharyngeal residue. Forty patients received de-intensified chemoradiation therapy (60 Gy image guided radiation therapy with weekly cisplatin 30 mg/m2) and 38 patients received standard-of-care chemoradiation therapy (70 Gy image guided radiation therapy with chemotherapy of the medical oncologist's choosing). Univariate and multivariate analyses were performed to detect differences between the cohorts with regard to laryngeal penetration, aspiration, and pharyngeal residue. A multivariate logistic regression was used to determine the overall effect of treatment on the swallowing function. Patient-reported swallowing outcomes in de-intensified cohort were assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Module for Head and Neck Cancer and the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events questionnaires. RESULTS: Patients treated with de-intensified chemoradiation therapy were associated with a suggestion of lower risk of developing overall swallowing dysfunction (odds ratio [OR], 0.62; P = .07), laryngeal penetration (OR, 0.63; P = .12), and pharyngeal residue (OR, 0.61; P = .08). The mean pre- and 2-year post-European Organisation for Research and Treatment of Cancer Quality of Life scores pertaining to swallowing (1-4 scale, higher worse) in the de-intensified cohort were 1.4 and 1.2 for liquids; 1.2 and 1.1 for purees; 1.5 and 1.7 for solids, 1.0 and 1.3 for choked when swallowing; and 9.0 and 10.8 for composite score, respectively. The mean pre- and 2-year post-Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events swallowing difficulty scores (1-5 scale, with higher scores being worse) were 1.5 and 1.8, respectively. CONCLUSIONS: Compared with 7 weeks of 70 Gy, 6 weeks of 60 Gy de-intensified chemoradiation therapy appears to better preserve the baseline swallowing function (per objective modified barium swallow assessment). Patients treated with de-intensified chemoradiation therapy reported minimal changes in swallowing function.
引用
- Judy GD, Green R, Aumer SL, et al. Preservation of swallowing function with de-intensified chemoradiation therapy for HPV-associated oropharyngeal squamous cell carcinoma. Adv Radiat Oncol. 2018. PMID: 30197941. doi:10.1016/j.adro.2018.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。